1-Phenethyl-3-chlormethyl-pyrrolidin | 101263-41-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Phenethyl-3-chlormethyl-pyrrolidin
• 英文别名: 3-chloromethyl-1-phenethyl-pyrrolidine；3-(Chloromethyl)-1-(2-phenylethyl)pyrrolidine
• CAS: 101263-41-6
• 化学式: C₁₃H₁₈ClN
• 分子量: 223.746
• InChiKey: WFBYCYHJWCVMJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] 1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY<br/>[FR] COMPOSES AZABICYCLIQUE DE 1H-PYRAZOLE ET 1H-PYRROLE SERVANT A EFFECTUER UN TRAITEMENT THERAPEUTIQUE
  申请人：UPJOHN CO

  公开号：WO2004013137A1

  公开（公告）日：2004-02-12

  The invention provides compounds of Formula (I), wherein Azabicyclo is Formula (I, II, III, IV, V, VI, VII); W is Formula (m); where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which α7 is known to be involved.

  这项发明提供了Formula (I)的化合物，其中Azabicyclo是Formula (I, II, III, IV, V, VI, VII); W是Formula (m); 其中变量的定义如本文所述。这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对于治疗已知涉及α7的疾病或症状的药物具有用处。
• [EN] COMPOUNDS AS RADIOLIGANDS FOR THE DIAGNOSIS OF DISEASE<br/>[FR] COMPOSES UTILISES COMME LIGANDS RADIOACTIFS POUR DIAGNOSTIQUER UNE MALADIE
  申请人：UPJOHN CO

  公开号：WO2004052889A1

  公开（公告）日：2004-06-24

  Radiolabeled ligands useful as probes for determining the relative abundance, receptor occupancy, and/or function of nicotinic acetylcholine receptors. The compounds of Formula I as described herein are labeled with a radioactive isotopic moiety such as 11C, 18F, 76Br, 123I or 125I. Disorders are diagnosed by administering to a mammal a detectably labeled compound and detecting the binding of that compound to the nAChR. The compounds that have been administered are detected using methods including, but not limited to, position emission topography and single-photon to emission computed tomography. The present invention is useful in diagnosing a wide variety of diseases and disorders as discussed herein.

  放射性标记的配体可用作探针，用于确定尼古丁乙酰胆碱受体的相对丰度、受体占有率和/或功能。本文描述的式I化合物标记有放射性同位素基团，如11C、18F、76Br、123I或125I。通过向哺乳动物注射可检测标记的化合物，并检测该化合物与nAChR的结合来诊断疾病。已经注射的化合物可使用包括但不限于正电子发射断层扫描和单光子发射计算机断层扫描在内的方法进行检测。本发明在诊断各种疾病和障碍方面具有实用性，如本文所述。
• Substituted-aryl compounds for treatment of disease
  申请人：——

  公开号：US20030236279A1

  公开（公告）日：2003-12-25

  The invention provides compounds of Formula I: 1 These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals to treat diseases or conditions in which &agr;7 is known to be involved.

  该发明提供了I式化合物：1这些化合物可以是药用盐或组合物的形式，可以是消旋混合物，也可以是其纯对映体。I式化合物在药物中用于治疗已知与α7有关的疾病或症状。
• [EN] N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS<br/>[FR] CARBOXAMIDES HETERO-BICYCLIQUES SUBSTITUES PAR N-AZABICYCLO, UTILISES EN TANT QU'AGONISTES DU RECEPTEUR DE L'ACETYLCHOLINE NICOTINIQUE
  申请人：UPJOHN CO

  公开号：WO2003037896A1

  公开（公告）日：2003-05-08

  The invention provides compounds of Formula (I), wherein Azabicyclo is I, II, III, IV, V, or VI; W0 is a bicyclic moiety and is (a), (b) or (c). These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.

  本发明提供式(I)的化合物，其中Azabicyclo为I、II、III、IV、V或VI；W0为双环基团，可为(a)、(b)或(c)。这些化合物可以是药物盐或组合物的形式，可以是纯对映体形式或混合物形式，并且在已知α7参与的药物中是有用的。
• N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1438308A1

  公开（公告）日：2004-07-21